Université De Nantes

Institut National De La Sante Et De La Recherche Medicale

Other

Centre National De La Recherche Scientifique

Centre Hospitalier Universitaire De Nantes

Institut Francais De Recherche Pour L'exploitation De La Mer (ifremer)

Chu Nantes

Institut Francais De Recherche Pour L'exploitation De La Mer

Dominique Heymann

Sylvia Colliec-Jouault

Corinne Sinquin

Jacqueline Ratiskol

Maxim Egorov

Jacques Lebreton

Carmen Ruiz-Velasco

Julie Chesneau

Aude Segaliny

Régis Brion

Stéphane Teletchea

Verena Stresing

Yannick Fortun

Marc Padrines

Francoise Redini

Françoise Redini

The invention provides a low-molecular-weight (15 kDa) over-sulfated exopolysaccharide (GYS15) prepared from a marine native exopolysaccharide excreted by a mesophilic marine bacterium from a deep-sea hydrothermal environment, and relates to the use of this low-molecular-weight over-sulfated exopolysaccharide for the prevention or inhibition of metastases formation.

Anti-metastatic marine bacterial exopolysaccharide derivative and uses thereof

The present disclosure relates to novel anti IL-34 antibodies or antigen-binding fragments thereof specifically binding cytokine IL-34 with high affinity, the method of obtaining of these antibodies and their therapeutic use.

Anti IL-34 antibodies

The present invention relates to a polypeptide for use as a medicament in the treatment and/or prevention of a disease wherein the RANKL-RANK signaling pathway is involved, in particular a bone resorptive disease.

Peptides targeting receptor activator of nuclear factor-&#x3ba;B (RANK) and their applications

The present invention relates to hydroxy-bisphosphonic acid derivatives corresponding to general formula (I): in which: -n and m denote, independently of one another, an integer ranging from 1 to 4, &#x2014;X denotes an oxygen atom or an N&#x2014;R3 group, &#x2014;R1 and R3 denote, independently of one another, a linear or branched Cto Calkyl group, and &#x2014;R2 denotes a residue of a molecule of therapeutic or diagnostic interest, or pharmaceutically acceptable salts of said derivatives, and also the method for the preparation thereof and the therapeutic or diagnostic use thereof. 

Hydroxy-bisphosphonic acid derivatives as vector targeting bone tissue

Growing community of inventors

Indre, France

Dominique Heymann